Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma

LAUR Repository

Show simple item record

dc.contributor.author Thomas, Ryan
dc.contributor.author Aloia, Thomas
dc.contributor.author Truty, Mark
dc.contributor.author Tseng, Warren
dc.contributor.author Choi, Eugene
dc.contributor.author Curley, Steven
dc.contributor.author Vauthey, Jean-Nicolas
dc.contributor.author Abdalla, Eddie
dc.date.accessioned 2015-11-20T07:40:42Z
dc.date.available 2015-11-20T07:40:42Z
dc.date.copyright 2014
dc.date.issued 2018-05-18
dc.identifier.issn 1365-182X en_US
dc.identifier.uri http://hdl.handle.net/10725/2638
dc.description.abstract Background The biology of hepatic epithelial haemangioendothelioma (HEHE) is variable, lying intermediate to haemangioma and angiosarcoma. Treatments vary owing to the rarity of the disease and frequent misdiagnosis. Methods Between 1989 and 2013, patients retrospectively identified with HEHE from a single academic cancer centre were analysed to evaluate clinicopathological factors and initial treatment regimens associated with survival. Results Fifty patients with confirmed HEHE had a median follow-up of 51 months (range 1–322). There was no difference in 5-year survival between patients presenting with unilateral compared with bilateral hepatic disease (51.4% versus 80.7%, respectively; P = 0.1), localized compared with metastatic disease (69% versus 78.3%, respectively; P = 0.7) or an initial treatment regimen of Surgery, Chemotherapy/Embolization or Observation alone (83.3% versus 71.3% versus 72.4%, respectively; P = 0.9). However, 5-year survival for patients treated with chemotherapy at any point during their disease course was decreased compared with those who did not receive any chemotherapy (43.6% versus 82.9%, respectively; P = 0.02) and was predictive of a decreased overall survival on univariate analysis [HR 3.1 (CI 0.9–10.7), P = 0.02]. Conclusions HEHE frequently follows an indolent course, suggesting that immediate treatment may not be the optimal strategy. Initial observation to assess disease behaviour may better stratify treatment options, reserving surgery for those who remain resectable/transplantable. Prospective cooperative trials or registries may confirm this strategy. en_US
dc.language.iso en en_US
dc.title Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal HPB en_US
dc.journal.volume 16 en_US
dc.journal.issue 7 en_US
dc.article.pages 677-685 en_US
dc.identifier.doi http://dx.doi.org/10.1111/hpb.12202 en_US
dc.identifier.ctation Thomas, R. M., Aloia, T. A., Truty, M. J., Tseng, W. H., Choi, E. A., Curley, S. A., ... & Abdalla, E. K. (2014). Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma. HPB, 16(7), 677-685. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://onlinelibrary.wiley.com/doi/10.1111/hpb.12202/full

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account